20 results about "Xeno free" patented technology

The present invention provides methods of producing in vitro derived neutrophils or macrophages in xenogen- and serum-free conditions from pluripotent stem cells and in vitro derived populations of neutrophils and macrophages. Methods of treatment using in vitro derived neutrophils or macrophages are also contemplated.

This invention discloses a xenogeneic-free culture method for hiPSCs and its quality monitoring method. The xenogeneic-free culture method includes the following steps: hiPSC cells are seeded into the wells of a culture plate coated with VTN-N matrix gel, and cultured for the first stage using E8 complete medium containing 5-15 µM Y-27632. After 20-30 h of culture, the medium is replaced with conventional E8 complete medium without Y-27632 for the second stage of culture, until the cell confluence reaches 60%-80%. This xenogeneic-free culture method ensures efficient cell expansion under conditions with clearly defined chemical composition. This method further optimizes the seeding density and culture period of hiPSCs, controls cell passage at 60%-80% confluence, and significantly reduces the risk of spontaneous differentiation by limiting the maximum culture time and upper limit of confluence.

Provided are novel serum-free culture media which comprise basic fibroblast growth factor (bFGF), transforming growth factor beta-3 and ascorbic acid at a concentration of at least about 50 microgram / ml; ascorbic acid at a concentration range of about 400-600 microgram / ml, bFGF at a concentration range of about 50-200 ng / ml, xeno-free serum replacement and a lipid mixture; the IL6RIL6 chimera at a concentration range of about 50-200 picogram per milliliter (pg / ml); or leukemia inhibitory factor (LIF) at a concentration of at least 2000 units / ml; cell cultures comprising same with pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem (iPS) cells, and methods of using same for expanding pluripotent stem cells in an undifferentiated state using two-dimensional or three-dimensional culture systems; and methods of expanding iPS cells in a suspension culture devoid of substrate adherence and cell encapsulation.

A biologic composition for promoting wound healing includes: a human mesenchymal stem cell (MSC)-derived extracellular matrix (ECM) biologic component, and a negatively charged polymer, combined with the biologic component to form the biologic composition. A method of preparing the biologic composition thereof includes: (i) isolating human mesenchymal stem cells (MSC) and subjecting the MSC to hypoxia-priming in a xeno- and / or serum-free, or chemically defined medium to stimulate the production of an MSC-derived biologic component with pro-angiogenic factors; (ii) aggregating and co-precipitating the MSC-derived biologic component with a negatively charged polymer into a pericellular space of the MSC to produce an aggregated biologic component; (iii) assembling the aggregated biologic component and the negatively charged polymer into an insoluble extracellular matrix (ECM) by the MSC; and (iv) decellularizing the insoluble ECM to obtain the biologic composition comprising MicroParticles of Solidified Secretome (MIPSOS).

Disclosed herein are methods and materials for transdifferentiating mesenchymal stem cells into neural progenitor cells.

The invention provides a non-heterogeneity serum-free culture medium for large-scale culture of human umbilical cord mesenchymal stem cells and a culture method. Specifically, the present invention provides a serum-free cell culture medium comprising a basic culture medium and additive components wherein the additive components comprise transferrin, insulin, selenium or a salt thereof, transforming growth factor-beta (TGF-beta), a platelet lysate composition, and a glutamine supplement. The invention further provides a method for culturing the mesenchymal stem cells through the culture medium and application of the mesenchymal stem cells. The culture medium disclosed by the invention has an excellent supporting effect on cell morphology, cell proliferation capacity, multiplication time and the like.

Disclosed is a method of producing ganglion progenitor cells from pluripotent stem cells and their use for treating ocular disorders. In particular, disclosed is a method of producing ganglion progenitor cells from pluripotent stem cells by transducing pluripotent stem cells with the neuronal differentiation transcription factor Neuronal Differentiation 1 (NEUROD1) in a chemically-defined and xenogenic-free culture medium and their use for treating ocular disease and / or an optic neuropathy.

Disclosed herein are methods for utilizing and forming suspension cultures of pluripotent stem cells (PSCs), and differentiated cells, spheroids, and organoids derived from PSCs (e.g., with industrial efficiency and / or scalability), as well as compositions comprising them. These methods can be carried out in suspension culture without the use of a basement membrane matrix during the maintenance and expansion of PSCs, and during the differentiation of PSCs into differentiated cells and organoids, such as endoderm (DE), hindgut spheroids (HGS), and intestinal organoids (IO). In some embodiments, the methods may be xenofree and may be carried out in accordance with Good Manufacturing Practices (GMP). Also disclosed herein are methods for controlling the polarity of epithelial cells in IOs, such that the apical layer is oriented outside the organoid, or alternatively inside the organoid. The use of methods and compositions for transplantation and therapeutic purposes is also disclosed.

A method for preparing targeted dermal papilla cell-derived exosomes is provided. The method involves first isolating a plurality of dermal papilla cells (DPCs) with a cell surface marker CD133 from the hair follicles of a healthy donor, in a xeno-free and serum-free environment in GTP lab in Taiwan (or GMP lab in international). Subsequently, a cell culture medium containing a plurality of exosomes is collected, wherein these exosomes possess surface markers such as CD9, CD63, and CD81. Finally, the exosomes are isolated, concentrated, and purified from the culture medium using techniques such as tangential flow filtration system (TFF system) or size exclusion chromatography, thereby obtaining the final targeted exosome lyophilized product. A liquid hair growth formulation formulated with this exosome product is also provided.

Provided are novel serum-free culture media which comprise basic fibroblast growth factor (bFGF), transforming growth factor beta-3 and ascorbic acid at a concentration of at least about 50 microgram / ml; ascorbic acid at a concentration range of about 400-600 microgram / ml, bFGF at a concentration range of about 50-200 ng / ml, xeno-free serum replacement and a lipid mixture; the IL6RIL6 chimera at a concentration range of about 50-200 picogram per milliliter (pg / ml); or leukemia inhibitory factor (LIF) at a concentration of at least 2000 units / ml; cell cultures comprising same with pluripotent stem cells such as human embryonic stem cells and induced pluripotent stem (iPS) cells, and methods of using same for expanding pluripotent stem cells in an undifferentiated state using two-dimensional or three-dimensional culture systems; and methods of expanding iPS cells in a suspension culture devoid of substrate adherence and cell encapsulation.

A composition comprising a hydrogel includes a polymer of formula (1), at least one repeating unit of which comprises BO2H2. Methods of making such hydrogels and methods of encapsulating cells using such hydrogels are also disclosed herein.

A method for producing an enriched population of human MSCs, comprising culturing isolated MSCs in xeno-free medium to at least 80% confluence, followed by treatment with a priming agent: erastin, sulfasalazine, or a combination thereof, to produce expanded MSCs positive for CD73, CD90, and CD105. A method is also provided for treating or preventing tissue damage or dysfunction, comprising the aforementioned method involving priming of human MSCs with a low dose of a priming agent. Further, a composition comprising primed MSCs and a cell culture medium system including the priming agent. Accordingly, the low-dose FINs offer a novel approach as a priming agent in large-scale stem cell expansion process. And the primed MSCs after low-dose FINs treatment could be applied to transplantation into oxidative and inflammatory microenvironments.

Provided are xenogenic-free methods and compositions for generating hematopoietic progenitors and natural killer (NK) cells in 3D suspension culture.

To provide a closed, automated and scalable stirred tank bioreactor platform, capable of sustaining high fold expansion of hPSCs.SOLUTION: Human pluripotent stem cells (hPSCs) are expanded in a controlled bioreactor using perfused xeno-free media. Cell harvest and concentration are performed in closed steps. The hPSCs can be cryopreserved to generate a bank of cells or further processed as needed. Cryopreserved cells can be thawed into a 2D tissue culture platform or a 3D bioreactor to initiate a new expansion phase or be differentiated to the clinically relevant cell type. The expanded hPSCs express hPSC-specific markers, have a normal karyotype and have the ability to differentiate to the cells of the three germ layers.SELECTED DRAWING: None

The present invention concerns a method of generating a population of skeletal muscle derived human muscle precursor cells. For this purpose, a specialized FBS-free cell growth medium is used. The invention further concerns a composition comprising such a population of hMPCs for use as a medicament, especially in the treatment of skeletal muscle dysfunction.

The present invention concerns a method of generating a population of skeletal muscle derived human muscle precursor cells. For this purpose, a specialized FBS-free cell growth medium is used. The invention further concerns a composition comprising such a population of hMPCs for use as a medicament, especially in the treatment of skeletal muscle dysfunction.

This invention relates to a method for inducing midbrain dopaminergic neurons and the neurons obtained therefrom. The solution provided by this invention provides a scaffold-based three-dimensional differentiation system for guiding the differentiation of human induced pluripotent stem cells into midbrain dopaminergic neurons. This system, as a scalable platform without xenogeneic component compatibility, has advantages in the efficient production of midbrain dopaminergic neurons and has wide applications in disease modeling, drug screening, and regenerative medicine.

The improved 4-5 day, optionally 3-5 day GMP-compliant in-vitro method enables the production of macrophages from monocytes that benefits from a shorter cell culture time, fewer interventions whilst maintaining the desired characteristics of the human macrophages. The present invention describes a method wherein the monocytes are cultured in medium comprising one or more growth factors to stimulate macrophages with a pro-regenerative phenotype. The method described herein is xeno-free, serum-free and GMP compliant. In addition, further disclosed are macrophages produced according to the present invention and the use of said macrophages in the treatment of liver diseases, such as liver cirrhosis.